# Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

> **NCT01410331** · PHASE2 · COMPLETED · sponsor: **Juventas Therapeutics, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **BIOLOGICAL:** JVS-100(4 mg) or placebo/8 injections
- **BIOLOGICAL:** JVS-100(8 mg) or placebo/8 injections
- **BIOLOGICAL:** JVS-100(8 mg) or placebo/16 injections
- **BIOLOGICAL:** JVS-100(16 mg) or placebo/16 injections

## Key facts

- **NCT ID:** NCT01410331
- **Lead sponsor:** Juventas Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410331, "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01410331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*